Navigation Links
BioDuro and Roche Expand Strategic Collaboration to Provide Drug Discovery Services
Date:4/6/2009

BEIJING, April 6 /PRNewswire/ -- BioDuro announced today that they have entered into a strategic partnership with Roche to support discovery phase research efforts at Roche's global research sites. BioDuro will provide research services in the areas of discovery chemistry and biology, which can help to shorten (internal) drug discovery timelines. This agreement is an expansion of an existing relationship.

Roche has many years of experience in partnering with external companies to complement its internal drug discovery expertise with external services and innovation. After extensive evaluation of many companies, Roche selected BioDuro as a strategic partner for this effort.

"Presently, there is intense competition within the CRO industry for outsourcing and drug discovery services, and the expectation is that they will deliver problem solving skills and innovation in both chemistry and biology," commented Robert Goodnow, Ph.D., Roche's Global Head of Medicinal Chemistry Outsourcing. "We selected BioDuro due to their demonstrated excellent performance in synthetic chemistry and ability to deliver integrated medicinal chemistry services."

"BioDuro is pleased to build upon this existing collaboration and work closely with the experienced team at Roche to aid in the development of novel therapeutics. We care deeply about working on projects that will impact the quality of life worldwide and working with Roche ensures this outcome. Our partnership demonstrates the strength of our innovative, fully integrated R&D service platform, and is a true testament to the caliber of scientists that have joined our team," commented John Oyler, Chief Executive Officer and co-founder of BioDuro LLC.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2008, sales by the Pharmaceuticals Division totalled 36.0 billion Swiss francs ($33.3B US), and the Diagnostics Division posted sales of 9.7 billion francs ($9.0B US). Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested nearly 9 billion Swiss francs ($8.3B US) in R&D in 2008. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.

About BioDuro

BioDuro is a US-based, fully-integrated, end-to-end, life science, research services company with a team of 580 in Beijing, China. BioDuro combines western pharmaceutical company quality and professionalism, with entrepreneurial, innovative biotech research culture, to leverage its talented, hard-working scientists. BioDuro's clients are over 40 pharmaceutical and biotechnology companies, including 10 of the top-12. BioDuro's services span the entire range of drug discovery and development, from discovery chemistry, discovery biology, early ADMET, DMPK, through pharmacology and drug safety evaluation.


'/>"/>
SOURCE BioDuro
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioDuro & The National Center for Safety Evaluation of Drugs Received Full AAALAC Accreditation
2. BioDuro and AstraZeneca Expand Collaboration to Optimize Discovery Research for Respiratory and Inflammation Indications
3. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
4. Roche Extends Tender Offer for Ventana
5. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
7. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
8. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
9. Med Ad News Honors Roche as Company of the Year
10. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
11. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... June 23, 2016 ... 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 Published recently ... peer-reviewed journal from touchONCOLOGY, Andrew D Zelenetz ... of cancer care is placing an increasing burden ... expensive biologic therapies. With the patents on many ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division of ... and optimized exclusively for Okuma CNC machining centers at The International Manufacturing Technology ... among several companies with expertise in toolholding, cutting tools, machining dynamics and distribution, ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
Breaking Biology News(10 mins):